Early-phase clinical trials (NCT03433781, NCT03397173) are underway to test the effects of ascorbic acid on MDS patients with TET2 deficiency in vivo. This evidence concerns the gene TET2 and hyperinsulinemic hypoglycemia, familial, 4.